Evidence map›Paper›PMID 28398294›Full record

ArticleProstate cancer and prostatic diseases2017

Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study.

H-J Shih, M-C Kao, P-S Tsai, Y-C Fan, C-J Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Cancer risk in Korean patients with gout.The Korean journal of internal medicine · 2022
    Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Association between allopurinol use and hepatocellular carcinoma in a case-control study in Taiwan.European journal of hospital pharmacy : science and practice · 2019
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

H-J ShihDivision of Urology, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.
M-C KaoDepartment of Anesthesiology, Taipei Tzu Chi Hospital, Taipei, Taiwan.
P-S TsaiGraduate Institute of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
Y-C FanDepartment of Anesthesiology, Taipei Tzu Chi Hospital, Taipei, Taiwan.
C-J HuangDepartment of Anesthesiology, Taipei Tzu Chi Hospital, Taipei, Taiwan.
Taipei Tzu Chi Hospital · TWChanghua Christian Hospital · TWTaipei Medical University · TWTzu Chi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical observations indicated an increased risk of developing prostate cancer in gout patients. Chronic inflammation is postulated to be one crucial mechanism for prostate carcinogenesis. Allopurinol, a widely used antigout agent, possesses potent anti-inflammation capacity. We elucidated whether allopurinol decreases the risk of prostate cancer in gout patients.

methodsWe analyzed data retrieved from Taiwan National Health Insurance Database between January 2000 and December 2012. Patients diagnosed with gout during the study period with no history of prostate cancer and who had never used allopurinol were selected. Four allopurinol use cohorts (that is, allopurinol use (>365 days), allopurinol use (181-365 days), allopurinol use (91-180 days) and allopurinol use (31-90 days)) and one cohort without using allopurinol (that is, allopurinol use (No)) were included. The study end point was the diagnosis of new-onset prostate cancer. Multivariable Cox proportional hazards regression and propensity score-adjusted Cox regression models were used to estimate the association between the risk of prostate cancer and allopurinol treatment in gout patients after adjusting for potential confounders.

resultsA total of 25 770 gout patients (aged between 40 and 100 years) were included. Multivariable Cox regression analyses revealed that the risk of developing prostate cancer in the allopurinol use (>365 days) cohort was significantly lower than the allopurinol use (No) cohort (adjusted hazard ratio (HR)=0.64, 95% confidence interval (CI)=0.45-0.9, P=0.011). After propensity score adjustment, the trend remained the same (adjusted HR=0.66, 95% CI=0.46-0.93, P=0.019).

conclusionsLong-term (more than 1 year) allopurinol use may associate with a decreased risk of prostate cancer in gout patients.

Indexed as

AdultAgedAged, 80 and overAllopurinolCase-Control StudiesGoutGout SuppressantsHumansMaleMiddle AgedProportional Hazards ModelsProstatic NeoplasmsRisk FactorsAllopurinolGout Suppressants

Identifiers

PMID28398294
OpenAlexW2606131470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.